Home > Cardiology > AHA 2021 > CVD Risk Reduction > Novel oral PCSK9 inhibitor shows promising results for hypercholesterolaemia

Novel oral PCSK9 inhibitor shows promising results for hypercholesterolaemia

Presented By
Dr Douglas Johns

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 175
Conference
AHA 2021
MK-0616, an oral PCSK9 inhibitor in development, was efficacious in lowering LDL cholesterol in patients with hypercholesterolaemia treated with statins and showed a favourable safety profile across two phase 1 trials. An oral PCSK9 inhibitor could help to overcome treatment barriers, providing cardiovascular risk reductions for patients with hypercholesterolaemia in an earlier phase. Dr Douglas Johns (Merck & Co., NJ, USA) mentioned that many patients with hypercholesterolaemia do not reach their LDL cholesterol treatment goals [1]. Although injectable PCSK9 inhibitors demonstrated LDL cholesterol reductions of 50–60%, these therapies are often administered as a last resort only. An oral PCSK9 inhibitor could remove the barriers associated with injectable treatments. A first randomised, double-blind, placebo-controlled, in-human trial assessed the safety and tolerability of single doses of MK-0616 ranging from 10 mg to 300 mg in 60 male partici...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on